Recent research shows, molecule-targeted medicine with epidermal growth factor receptor (EGFR) as a therapeutic target may effectively improve responses to treatment and prolong progression-free survival (PFS), playing an essential role in the treatment of NSCLC (1, 4, 5), which mainly consists of two types: small-molecule tyrosine kinase inhibitors (TKIs) like afatinib, gefitinib, icotinib, as well as monoclonal antibodies (6). Here, EGFR is linked to non-small cell lung carcinoma.